We know that collaborating with the research community is important, but how do we make sure that this is the right thing to do for PLHIV? We are committed to working with PLHIV to truly understand their experiences and needs. In addition to our active collaborations, we support more than 200 studies around the world, accelerating our ability to develop a robust and diverse pipeline for PLHIV. By merging our expertise in the HIV Cure Centre and Qura Therapeutics to foster innovation and the discovery of new medicines, we’re sourcing the best science and thinking from around the world to accelerate novel breakthroughs and maximise our chances of finding a cure. In 2020, we announced the renewal of our collaboration with the UNC-Chapel Hill that is solely focused on finding a cure for HIV. Using that information, the goal is to identify early stage drug targets that we could use to develop new medicines or approaches to treat HIV infection. The HFGP is a large-scale project that identifies factors that help us better understand how the body recognises and defends itself from disease, as well as the signs, symptoms and progression of disease. In 2019, we announced a five-year collaboration with Radboud university medical centre (Radboudumc) in Nijmegen, The Netherlands, providing dedicated funding to enhance the HIV-specific capability of the Human Functional Genomics Project (HFGP). However, the needs of PLHIV change over time, and we‘re exploring new ways of treating and preventing HIV through new mechanisms of action and drug delivery.ĭespite the advances in HIV treatment, there are still many unanswered research questions that we need help to address. Over the last 40 years there have been incredible advances in the development of effective HIV treatments that allow people living with HIV (PLHIV) to suppress their virus to undetectable levels. AstraZeneca also announced they would work with Oxford University on the global development and distribution of a COVID vaccine 2.Īt ViiV Healthcare our goal is simple to end the HIV epidemic. Our majority shareholder, GSK, teamed up with Sanofi in an unprecedented vaccine collaboration to fight the COVID-19 pandemic 1. The board members start official duties once the legislation commences, likely in early September 2022.We’ve got more than 50 active collaborations worldwide with pharmaceutical and biotechnology companies, government agencies, academic institutions and not-for-profit organisations to broaden our capabilities and enhance our performance.Ĭollaboration within the healthcare community isn’t new, but 2020 served as a great example of just how important it can be to address health challenges around the world. Legislation to establish the Collaborative Centre passed Parliament in November 2021. The purpose-built facility in Melbourne will bring together people with lived experience, researchers and clinicians to establish best practice in adult mental health and wellbeing services, including conducting research and sharing knowledge. The Collaborative Centre will serve as the ‘engine room’ of the reformed mental health and wellbeing system. This includes setting the early strategic direction of the new centre and selecting key delivery clinical and academic partners. The board will oversee the establishment and operation of the new Collaborative Centre. This includes two people who bring a consumer perspective and two with family, carer or supporter perspective. The board has at least four people who identify as having a lived experience of mental illness or psychological distress. The appointments bring a broad depth of personal and professional experiences to the board. The establishment of the Collaborative Centre is a key recommendation of the Royal Commission into Victoria’s Mental Health System.įor more information about the board members, visit Victorian Collaborative Centre for Mental Health and Wellbeing.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |